| Pritish Bhattacharyya, MD | |
|
30 Prospect Ave, Hackensack, NJ 07601-1914 | |
| (201) 996-2000 | |
| Not Available |
| Full Name | Pritish Bhattacharyya |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 51 Years |
| Location | 30 Prospect Ave, Hackensack, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144258872 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 25MA06576300 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackensack University Medical Center | Hackensack, NJ | Hospital |
| Jersey Shore University Medical Center | Neptune, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hackensack Pathology Associates, Llc | 2365589298 | 16 |
News Archive
A new report by researchers at RTI Health Solutions and parent company RTI International, found that although healthcare databases have allowed for greater access to real world medical data, using databases to evaluate the safety of medical products is complex and requires careful research consideration.
Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).
Over the past few years, scientists have discovered that a new class of genetic regulators called "microRNAs" influences normal human growth and development. Now, researchers have found that microRNAs also play an important role in human cancer. The findings are published in tomorrow's issue of the journal Nature (June 9).
Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced that they will partner with the Wills Eye Institute in Philadelphia as the lead U.S. clinical trial investigator site.
› Verified 1 days ago
| Entity Name | Regional Cancer Care Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801850243 PECOS PAC ID: 5294710091 Enrollment ID: O20040623001494 |
News Archive
A new report by researchers at RTI Health Solutions and parent company RTI International, found that although healthcare databases have allowed for greater access to real world medical data, using databases to evaluate the safety of medical products is complex and requires careful research consideration.
Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).
Over the past few years, scientists have discovered that a new class of genetic regulators called "microRNAs" influences normal human growth and development. Now, researchers have found that microRNAs also play an important role in human cancer. The findings are published in tomorrow's issue of the journal Nature (June 9).
Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced that they will partner with the Wills Eye Institute in Philadelphia as the lead U.S. clinical trial investigator site.
› Verified 1 days ago
| Entity Name | Hackensack Pathology Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184856031 PECOS PAC ID: 2365589298 Enrollment ID: O20091027000288 |
News Archive
A new report by researchers at RTI Health Solutions and parent company RTI International, found that although healthcare databases have allowed for greater access to real world medical data, using databases to evaluate the safety of medical products is complex and requires careful research consideration.
Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).
Over the past few years, scientists have discovered that a new class of genetic regulators called "microRNAs" influences normal human growth and development. Now, researchers have found that microRNAs also play an important role in human cancer. The findings are published in tomorrow's issue of the journal Nature (June 9).
Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced that they will partner with the Wills Eye Institute in Philadelphia as the lead U.S. clinical trial investigator site.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pritish Bhattacharyya, MD Po Box 23650, Newark, NJ 07189-0001 Ph: (800) 832-8244 | Pritish Bhattacharyya, MD 30 Prospect Ave, Hackensack, NJ 07601-1914 Ph: (201) 996-2000 |
News Archive
A new report by researchers at RTI Health Solutions and parent company RTI International, found that although healthcare databases have allowed for greater access to real world medical data, using databases to evaluate the safety of medical products is complex and requires careful research consideration.
Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).
Over the past few years, scientists have discovered that a new class of genetic regulators called "microRNAs" influences normal human growth and development. Now, researchers have found that microRNAs also play an important role in human cancer. The findings are published in tomorrow's issue of the journal Nature (June 9).
Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced that they will partner with the Wills Eye Institute in Philadelphia as the lead U.S. clinical trial investigator site.
› Verified 1 days ago
Min W Han, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 201-996-2000 | |
Dr. Maher Albitar, Pathology Medicare: Accepting Medicare Assignments Practice Location: 92 2nd St, Hackensack, NJ 07601 Phone: 551-996-5806 | |
Carol J Fehmian, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 201-996-2000 | |
Aaron Sohn, MD Pathology Medicare: Medicare Enrolled Practice Location: 30 Prospect Ave., Hackensack, NJ 07601 Phone: 551-996-2000 | |
Michael J Goldfischer, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 201-996-2000 | |
Xiao Yan Yang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 201-996-2000 |